Drug Trial Radar · NCT07766421
Evaluation of Iopofosine I 131 vs. R-CD in WM Patients
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
219
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jan 2032
Study completion Jan 2035
Sponsor
- Lead sponsor
- Cellectar Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate whether iopofosine I 131 is more effective than the combination Rituximab-Cyclophosphamide-Dexamethasone (R-CD). The main question the study aims to answer is: • Does iopofosine I 131 work better than R-CD when looking at the length of time during and after the treatment that a patient lives with WM but it does not get worse. Participants will: * Be randomly assigned to received either iopofosine I 131 or R-CD. * If assigned to iopofosine I 131, have it administered via infusion 2 times each cycle for a total of 2 cycles (each cycle is about 3 months long). * If assigned to R-CD, it will be administered for up to six cycles, and each cycle is 3-weeks long * Visit the clinic once every 3 weeks for checkups and testing. * Report any side effects or new medications.
Conditions
- Waldenstrom Macroglobulinaemia
- Waldenstrom Macroglobulinemia
- Waldenstrom's Macroglobulinaemia Refractory
- Waldenstrom Macroglobulinemia With Nodal Disease
- Waldenstrom's Macroglobulinemia Recurrent
Interventions
Iopofosine I 131Drug
Fractionated dose
Rituximab (active comparator)Drug
Rituximab
CyclophosphamateDrug
Cyclophosphamide
DexamethasoneDrug
Dexamethasone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Superiority of progression free survival (PFS)Time frame: From baseline randomization through study completion of progressive disease, or death due to any reason (whichever status is recorded first).
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.